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The development of a public optometry system
in Mozambique: a Cost Benefit Analysis
Stephen Thompson1*, Kovin Naidoo2, Geoff Harris3, Luigi Bilotto4, Jorge Ferrão5 and James Loughman1

Abstract
Background: The economic burden of uncorrected refractive error (URE) is thought to be high in Mozambique,
largely as a consequence of the lack of resources and systems to tackle this largely avoidable problem. The
Mozambique Eyecare Project (MEP) has established the first optometry training and human resource deployment
initiative to address the burden of URE in Lusophone Africa. The nature of the MEP programme provides the
opportunity to determine, using Cost Benefit Analysis (CBA), whether investing in the establishment and delivery of
a comprehensive system for optometry human resource development and public sector deployment is
economically justifiable for Lusophone Africa.
Methods: A CBA methodology was applied across the period 2009–2049. Costs associated with establishing and
operating a school of optometry, and a programme to address uncorrected refractive error, were included. Benefits
were calculated using a human capital approach to valuing sight. Disability weightings from the Global Burden of
Disease study were applied. Costs were subtracted from benefits to provide the net societal benefit, which was
discounted to provide the net present value using a 3% discount rate.
Results: Using the most recently published disability weightings, the potential exists, through the correction of URE
in 24.3 million potentially economically productive persons, to achieve a net present value societal benefit of up
to $1.1 billion by 2049, at a Benefit-Cost ratio of 14:1. When CBA assumptions are varied as part of the sensitivity
analysis, the results suggest the societal benefit could lie in the range of $649 million to $9.6 billion by 2049.
Conclusion: This study demonstrates that a programme designed to address the burden of refractive error in
Mozambique is economically justifiable in terms of the increased productivity that would result due to its
implementation.
Keywords: Optometry, Cost benefit analysis, Health economics, Mozambique, Uncorrected refractive error,
Eye health, Human resource development, Blindness, Visual impairment, Higher education

Background
Refractive error occurs when the eye cannot clearly focus
incident light on the retina, resulting in blurred vision. It
refers principally to the conditions of myopia, hyperopia,
and astigmatism, while presbyopia represents a related,
and age dependent, inability to focus clearly on near objects. Uncorrected refractive error (URE) is the leading
global cause of low vision, and causes almost half of all visual impairment (VI) [1]. It is recognised as a priority public health condition by a joint programme of the World
Health Organization and the International Agency for the
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Prevention of Blindness under the global initiative, VISION 2020 [2]. Addressing URE is a priority, not just because of the burden of blindness and VI that it is
responsible for, but also because of how easily and affordably it can be treated [3]. URE hampers education, limits
employment opportunities, reduces productivity, and has
been shown to impair quality of life [1,3]. Simple and effective eye health interventions including an eye exam and
provision of suitable spectacles can address the burden of
URE [4].
In Mozambique, the burden of URE is thought to be
high, having a severe impact on the livelihoods and wellbeing of disadvantaged communities [5]. A Rapid Assessment of Refractive Error (RARE) study in Mozambique
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found the prevalence of vision impairment was 3.5% (95%
CI 49 2.7% - 4.2%), with 65.8% of those visually impaired
being 35 years of age and older. URE prevalence was 2.6%
(95% CI 2.1%-3.2%), and was the primary cause of vision
impairment among 64.5% of cases. The spectacle coverage
for URE was 0%. Presbyopia prevalence was higher, at
25.8% (95% CI 12.0% - 30.5%), with only 2.2% spectacle
coverage [6]. By comparison, a RARE study completed in
Eritrea found URE prevalence was 6.4% (95% CI 5.6%7.2%) and spectacle coverage of 22.2%, while for presbyopia prevalence was 32.9% (95% CI 30.3%-35.7%) with
spectacle coverage of 9.9% [7]. This comparison indicates
how poorly developed and inaccessible refractive error services are in Mozambique compared to Eritrea.
The Mozambique Eyecare Project (MEP) is a partnership to facilitate the development, implementation and
evaluation of the first and only optometry programme in
Mozambique. This includes the establishment of a fouryear BSc optometry course at Universidade Lúrio, a
public university, in Nampula, northern Mozambique.
Graduates are expected to work in the public health system once qualified. The recently founded programme
presented a unique opportunity for Cost Benefit Analysis
(CBA) to determine whether investing in optometry is
economically justifiable.
Economic analysis is used to inform health planners
and policy makers how limited resources should be allocated, indicating which interventions are good value for
money. It can assist with justifying decisions on different
resource allocation pathways [8]. CBA compares the resources spent on an intervention to the benefits gained
or resources saved as a result of the intervention. It is
useful for demonstrating savings associated with healthcare policy decisions [9], and can be used to gauge the
desirability of an intervention in terms of its economic
worth to society [10].

Methods
Ethical approval was granted for the study under the
Mozambique Eyecare Project (a joint initiative of Dublin
Institute of Technology, University of Ulster, Universidade Lúrio and Brien Holden Vision Institute) by Dublin
Institute of Technology, Republic of Ireland. Cost Benefit Analysis methodology was applied across the period
2009–2049. All costs were converted into United States
Dollars ($). Costs were calculated using multiple resources including MEP financial reports, current market
price information, and national human resources data.
They included all costs associated with the establishment
of an optometry degree programme, the establishment
of vision centres within public hospitals, human resources costs, and overheads. The initial costs incurred
during the implementation period were met by the MEP
partners. Future costs may be met by the MEP partners,
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a range of funders, organisations interested to be involved in the partnership, and national government. The
benefits associated with students enrolling in the last
four years of the analysis period were omitted, although
the costs associated with their education were included
to reflect the on-going nature of the programme. Costs
were subtracted from benefits to provide the net societal
benefit, which was discounted to provide the net present
value using a 3% discount rate to factor in the time value
of money [11,12]. Costs and benefits from years 2
through to 41 were discounted to the present value at
the start of the program in 2009. Benefits were calculated using a human capital approach to valuing sight,
measuring the potential economic productivity foregone
by not addressing URE. Potential productivity gained by
addressing URE was estimated using the value of $1,200
as Gross Domestic Product (GDP) adjusted for Purchasing Power Parity (PPP) per capita as a proxy indicator
[13]. It was assumed that optometrists would work
242 days per annum, on average correcting the URE of
15 patients who are potentially economically productive
per day (conservatively based on existing hospital clinic
sessions staffed by ophthalmic technicians who examine
30–40 patients per day). A Labour Force Participation
Rate (LFPR) of 82.75% and an Employment Rate (ER) of
79% were included to reflect the labour market and the
fact that the emergence of productivity is not a certainty
[13,14].
The potential impact of visual impairment on productivity was calculated by applying disability weightings (DWs),
used to quantify the severity of a disease or condition
through a scale where 0 represents perfect health, 1 represents death, and every point in between reflects a level of
disability associated with the specific disease or health
condition, to PPP-adjusted GDP per capita. DWs for VI
detailed in the 2010 Global Burden of Disease (GBD)
study were incorporated into the analysis [15]. The original GBD study detailed a single DW for all categories of
VI [11]. For the revised study, VI was divided into four categories [16], with each category assigned lower DWs than
the original DW, as displayed in Table 1.
Prevalence data of VI from previous studies informed
distribution across the categories [17]. Due to limited data
distinguishing between mild and moderate VI, these two
categories combined into one and an average DW of
0.0185 assigned. To keep the analysis conservative, only
the revised DWs for VI were used and the productivity
loss associated with blindness (visual acuity < 3/60) was
not included in the current study. Although the new DWs
were used for the main body of this study, the original
DW were included as part of the sensitivity analysis.
Spectacles were assumed to provide an effective solution to URE for up to four years once dispensed, based
on studies in Africa, Asia, America and Europe [18,19].
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Table 1 VI category definition by visual acuity* in the
better eye and associated new DWs

Mozambican lecturers costs

VI category

Definition

DW

Distance mild VI

<6/12 but ≥6/18

0.004

Distance moderate VI <6/18 but ≥6/60

0.033

Distance severe VI

<6/60 but ≥3/60

0.191

Near VI

<6/12 but ≥3/60 for near, but ≥6/12 for
distance

0.013

*Snellen visual acuity or the equivalent calculated from published LogMAR values.

The first optometrists graduated in 2013, but those
selected to teach will need additional pedagogic training before they are ready to be educators. The first
Mozambican optometrist lecturers were scheduled to be
employed in 2015, working alongside expatriate lecturers
during a transition period. By 2017 all lecturers were
assumed to be Mozambican, at a cost of $18,514 per
annum per lecturer.

Further research is needed to establish whether this assumption is suitable specifically in the Mozambican context. To take into account prescription instability and
spectacle frame/lens durability, effectiveness was assumed to be 100% in years one and two, 75% in year
three and 50% in year four. After the fourth year the patient would return to suffering fully restricted productivity through URE and would need to return to the
optometrist. The net benefit or loss was calculated by
subtracting costs from benefits.
The population growth rate was assumed to stay constant at 2.3% per annum [20]. Seven students from the pilot
group were assumed to enter the public system after
graduation, with 15 expected to enter every subsequent
year. The analysis period of 2009 to 2049 was defined by
the time it would take, at such graduation rates, to reach a
ratio of approximately one optometrist per 100,000 people,
as shown in Table 2. This ratio represents half of the
VISION 2020 target of one optometrist per 50,000 people
[21]. Student numbers are already higher than those in
this analysis but conservative graduation rates were selected to take into account death, career change, and
decision not to work in the public sector.

Management costs

Results

Faculty operating costs

Costs
Expatriate lecturers costs

To reflect the general cost of running the university,
$800 per student per annum was included (university
estimate).

Expatriate lecturers were employed to teach until local
human resources become available to take over. It was
assumed 25 teaching years would be needed to reach
this position. A staggered transition from expatriate to
local faculty was assumed in order to ensure minimum
impact to the students’ educational experience. The cost
of $45,000 per annum per expatriate lecturer, based on
actual incurred MEP costs, was included.

MEP Management costs included advocacy, project and
financial management, procurement, research and human resource development. Costs were $1.7 million over
the first six years, to reflect the assigned Programme for
Strategic Cooperation funding from Irish Aid and the
project partners. A rate of $100,000 per annum was applied thereafter, to reflect on-going support from the
partners, which will depend on securing new funding
once the original funding phase has ended.
School equipment costs

In the first four years $330,000 was spent on the purchase and maintenance of equipment, with a rolling cost
of $50,000 per annum applied thereafter.
Educational material costs

During the first four years, the actual cost of developing
and translating educational materials was $126,000, with
$5,000 per annum every year thereafter.
Book/academic literature costs

The cost of $3,000 per annum was assigned for books
and academic literature.

Vision centre equipment costs

Once graduated, it was assumed that optometrists would
work in Vision Centres, installed in existing public health
facilities. A Vision Centre, designed to support two optometrists was calculated to cost $45,250. Costs included
equipment, refurbishment/renovations, transport including

Table 2 Predicted population trends and number of optometrist graduates over time
Year

2019

2029

2039

2049

Predicted population (million)*

28.7

36

45.2

56.8

Cumulative number of graduates

97

247

397

547

Optometrists per head of population

296,023

145,934

113,977

103,843

*Based on the population growth rate staying constant at 2.3% per annum [20].
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shipping and customs, management time, support costs,
monitoring and evaluation and project management costs.
Vision centre human resource costs (Optometrists)

The public sector salary of an optometrist with less than
three years of experience was confirmed as $9,528 per
annum, increasing to $9,912 per annum after three years
of service.
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Table 3 Net present value of costs 2009 – 2049 after
applying a 3% discount rate
Cost

$

%

Expatriate teaching faculty

1,013,912

1.2

Local teaching faculty

1,669,727

2.0

Programme management costs

3,419,385

4.1

School equipment cost

1,329,116

1.6

Educational material costs

221,578

0.3

Vision centre human resources costs (Technicians)

Book costs

72,344

0.1

Each location was also assumed to require a technician
to support the clinics, maintain equipment, and to assist
with the manufacturing of spectacles bespoke to each
patient. The salary of $3,503 per employee per annum
was included.

General faculty operating costs

4,753,419

5.7

Vision centre equipment costs

6,737,416

8.0

Vision centre human resources costs (optometrists)

45,404,417 54.1

Vision centre human resources costs (technicians)

8,099,332

9.7

Vision centre human resources costs (administrators) 8,099,332

9.7

Vision centre human resources costs (Administrators)

Overheads

3,100,461

3.7

Each location was also assumed to require one administrator, who would receive the salary of $3,503 per
annum.

Total

83,920,439 100.0

Vision centre overheads costs

For use of electricity, water, and basic upkeep of the
building, $672 per optometrist per annum was included.
Significant building repair have not been included in this
analysis.
Between 2009 and 2049, after applying a 3% discount
rate the net present value of the cost of training and
employing optometrists was $83.9 million, as shown in
Table 3. The salaries of the optometrists represented by
far the highest proportion of costs, accounting for 54.1%
of the total.
Benefits

Economic benefits are not realised until the fifth year
(2013) when the first optometrists graduate and enter
the public health system. By 2049, after applying a 3%
discount rate, a net present value gross societal benefit
$1.2 billion using the new DWs. This represents the
value of correcting the URE of 24.3 million patients who
are potentially economically productive.
Cost benefit analysis

Using the new DWs, the present value of the annual net
societal benefit is negative until 2014. From 2014 there
is a positive annual net societal benefit. This continues
until the end of the analysis. By 2049, a net present value
of $1.1 billion in societal benefits is realised. The results
are illustrated in Figure 1.
The Benefit-Cost Ratio (BCR) can be used to evaluate
the economic merit of a programme. A ratio where the
benefits are greater than 1 suggests the programme is
economically justifiable. Using the new DWs after discounting, the BCR is 14:1. The cumulative net societal

benefits are positive by 2049. Initial costs associated with
implementing the programme are eclipsed by the much
higher benefits realised in later years.
Sensitivity analysis

Methodological sensitivity to the discount rate was
tested, and the results indicated that the outcome of the
study did not change until a 72% discount rate was applied, at which point the net present value of societal
benefits for new DWs became negative. Without any
discounting, a total of $2.5 billion in societal benefits are
recorded by 2049.
Further investigation into the sensitivity of the methodology was implemented by comparing four scenarios
based on different assumptions. Scenario 1 was the most
conservative in comparison to the other three. It assumed that spectacles would only be effective for two
years instead of four years and the salary of optometrists
was doubled. It employed the revised DWs. Scenario 2
employed the same assumptions as scenario 1, but maintained the salaries at the original level detailed in the
main body of the study. Scenario 3 represented the assumptions used in the main analysis and were included
to allow comparison. Scenario 4 was the least conservative. It employed the same assumptions as scenario 3,
but used the original DW as opposed to the new DWs.
Scenario 1 found that by 2049, $649 million in societal
benefits would be realised. Scenario 2 found that by 2049,
$695 million in societal benefits would be realised. As described in the main analysis, scenario 3 resulted in a net
societal benefit of $1.1 billion by 1949. For the first 3 scenarios the annual net societal benefit is negative until
2013 and positive from 2014 until the end of the time
period analysed. Scenario 4 found that the annual net
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Figure 1 Costs and benefits of the optometry programme with 3% discounting.

societal benefit is negative until 2012. From 2013 until the
end of the time period analysed, it is positive. By 2049, a
net present value of $9.6 billion of societal benefits will
have been realised. Figure 2 illustrates the results of the
sensitivity analysis, showing the NPV of societal benefits
at 3% discount rate for the four scenarios analysed.
The sensitivity analysis found that regardless of parameter changes to assumptions made about the costs, benefits or disability weighting, a positive net societal benefit
is realised very soon after the optometrists graduate and
commence work. Even when assumptions were extremely conservative, $649 million in societal benefits
could be realised by 2049. When less conservative assumptions were used, the model found that $9.6 billion
in societal benefits could be realised by 2049.

Discussion
During the early years of the programme, funds are
spent to establish the optometry school but no benefits
are realised until the first optometrists start work. This
period of high costs and no return is to be expected as a
normal implementation phase for any human resources
development programme. In the years following the implementation phase, the annual BCRs indicate a positive
return on investment. With competition for limited resources and funds coming from both outside and within
health systems, optometry is shown to be worthy of investment due to the potential for societal benefit. The
results complement those of existing literature, which
found interventions that address URE to be economically justifiable [1,4,17,22].

Figure 2 The results of the sensitivity analysis, showing the NPV of societal benefits ($) at 3% discount rate.
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The new DWs for blindness and VI have been the subject
of much debate. The Vision Loss Expert Group (VLEG),
comprising of leading ophthalmologists and optometrists,
has expressed concern at how low the new DWs are compared to the previous weighting, particularly noting variations in the formulation of the lay survey questions
pertaining to different health conditions. Vision and hearing
loss are notable outliers in the 2010 GBD study. When
compared to the assigned DWs for moderate skin disfigurement with itch or pain (0.187), mild alcoholism (0.259),
moderate rheumatoid arthritis (0.292), or even a pain in the
neck (0.221), the VLEG authors note that the new DWs for
blindness and VI simply do not pass the “common sense
test”. VLEG calls for the new DWs to be investigated further prior to their widespread adoption [23]. The GBD authors have defended the new DWs, by stating that the
definitions of blindness and VI were informed through consultation with VLEG and that the weights were informed by
a series of measurement surveys, in which 30,000 people
participated. They also issued a warning not to use previous
weights as if they were a reference standard [24]. The results of this study exemplify the impact that revising DWs
can have on the assessment of an intervention. In the case
of the burden of URE as addressed herein, the range of societal benefits that are projected vary nine fold, from $1.1
billion for the revised DWs to $9.6 billion for the original
DW. Many CBA methodologies are available, and different
theories exist in relation to which costs and benefits to include. In the current study no building costs were included
as the Universidade Lúrio campus was already established.
Also the costs of lenses and frames were excluded, as the
spectacles would be sold at least for a nominal fee to cover
costs. To keep the analysis conservative, net profit from sale
of spectacles was not included. This revenue has potential
to contribute not only to the economic stability and sustainability of the refraction service, but of a complete eye
health department [17,25,26].
The current study does not address people’s willingness to
pay, ability to pay or any barriers to access for a refractive
service. Quality of delivery, as well as supply and distribution
processes will determine how successful the programme is
[4,27]. Further research on this is needed. Acceptance is also
a factor. The compliance ratio has a direct relationship with
the benefits realised. The study assumes 100% spectacle
wear compliance for patients with refractive error, which
may not be the case. If half of the patients rejected the
spectacles or took them but never wore them, then the benefits would also be reduced by half. Also, addressing URE
does not guarantee the emergence of economic productivity.
The conditions and environment will need to be conducive
to economic opportunity or entrepreneurial opportunity for
productivity to flourish after URE is addressed.
As in any CBA study, judgements were made concerning
the inclusion of cost and benefit items and assumptions
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were made concerning their size and/or incidence. For the
base case scenario, these judgements were always conservative and so reduced the estimated societal benefit. The sensitivity analysis tested the robustness of the methodology
against changing assumptions.
Inflation costs were deliberately excluded. In periods of
inflation, market prices and costs do not measure true
values of benefits and costs. The values of benefits and
costs appear to increase although their true value does not.
Real values are values with the purchasing power of money
held constant relative to a specific point in time [10].
This study builds on existing literature, in which economic analyses have been employed to estimate the
value derived from addressing blindness and VI. One
study found that addressing URE has the potential for
the greatest impact on the global economy compared to
all other preventable vision disorders [28]. Another
found investing in eye health in The Gambia to be economically justifiable and a third found that globally, in
excess of $100 billion in lost productivity could be
avoided if all the targets set by VISION 2020 are
achieved for the period from 2003 to 2020 [11,12]. Focusing exclusively on the impact of VI caused by URE
on economic productivity, it was estimated that the global loss associated with this burden was $268.8 billion
after adjustment for LFPR and ER. While direct comparison between studies is challenging due to differences
in scale and scope, both the global study and the current
national level study for Mozambique provide sound economic reasoning to invest in interventions that address
URE and reduce the burden of VI [28].
The study assumes that the graduation rate remains
constant after the pilot year. In reality, the number of
students and optometrists will increase as the course becomes more established and the cadre develops. The enrolment rate in the study was deliberately conservatively
low. If enrolment increased, so would some costs, but
not all. For example, educational material costs would
stay the same, but school equipment costs would need
to increase in proportion to the number of students. If
the CBA model is updated to assume double the number
of students graduate each year, to represent the VISION
2020 target of one optometrist per 50,000 people, subject to a 3% discount rate, a net present value societal
benefit of $2.3 billion when using the new DWs could
be realised by 2049. This represents the value of correcting the URE of 48.6 million patients who are potentially
economically productive by 2049. The annual BCR remains virtually static as an increase in students and
graduates increases both the costs and benefits.
The focus of the current study is URE but optometrists
can also reduce the burden of blindness and VI caused by
other diseases and conditions - the benefits of which are
not reported here. Blindness and VI are further associated
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with additional indirect health effects and costs. An effective programme to address avoidable vision loss will generate cost savings, as, for example, the rates of falls,
fractures, motor vehicle accidents and conditions such as
depression attributable to low vision are reduced. Premature death due to blindness and VI would also result in a
future stream of productivity losses due to lost potential
earnings. Such indirect cost savings and productivity gains
are difficult to accurately quantify, and, therefore, not included in the model, but would serve to increase the net
societal benefit.
Although URE is also a cause of blindness (visual acuity < 3/60) which is afforded higher DWs relative to VI
(Original DWs, 0.6; revised DWs 0.195), the prevalence data
on blindness associated with URE is inconsistent, ranging
from 1.1% to 7.9% in some studies, but with more than half
of all studies across sub-Saharan Africa reporting zero blindness as a consequence of URE [29]. Due to the likely low
overall blindness prevalence as a result of URE, the current
study includes visual impairment only, which reinforces the
conservative nature of the societal benefit estimate.
Also, the burden of URE is, in reality, not limited to
just the individual who is visually impaired. Families, societies and communities may also suffer the burden as
they may be required to give up their time to perform
certain tasks to assist or care for the person with VI.
One study assumed that for each blind individual, a 10%
loss of productivity would be experienced by a relative
or someone in the community [11]. If the wider societal
burden were to be included, net societal benefits of addressing the URE would increase. The current study focuses on people of productive age. It does not consider
that if the URE of a child is addressed, this would be expected to maximise their future economic productivity
through improved education and consequentially enhanced employment opportunities.

Conclusion
The development of optometry has been shown to have the
potential to achieve a net present value societal benefit of
$1.1 billion by 2049 in Mozambique using conservative
DWs and after applying a 3% discount rate. Investment in
optometry is shown to be attractive and justifiable in economic terms. When CBA assumptions are varied as part of
the sensitivity analysis, the results suggest the societal benefit could lie in the range of $649 million to $9.6 billion by
2049, depending on how conservative the assumptions are.
While costs can be justified, as they are far outweighed by
the benefits optometrists bring, they still present a large
cash outflow for the public health sector of a low income
country. Careful planning is needed to ensure the budget
is available to employ the optometrists once trained
within the public sector. If the budgetary resources are
not available to pay the optometrists wages, they will
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either seek employment in the private sector or possibly
look to emigrate. Either of these scenarios would result
in the burden of URE in Mozambique remaining high.
To conclude, the results reinforce observations from
other national and international eye health studies that
suggest that investment in eye health, and particularly
programmes that address URE, provide good value for
money and can be justified economically.
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